2.1. Study Design and Settings
SECONDARY
This clinical trial is a prospective, single-center, double-blind, randomized clinical trial conducted in the rehabilitation department of our hospital from June 2019 to September 2022. Patients were randomly assigned to receive either 20 days of conventional gait rehabilitation therapy (CGR) combined with ctDCS treatment (trial group) or sham-stimulated tDCS treatment plus CGR (control group). All patients were treated with tDCS for 20 min once a day for 20 consecutive days based on CGR therapy. The primary and secondary outcomes of the patients were evaluated before treatment (T0), immediately after the treatment (T1), and one month after the end of the treatment (T2). All patients were evaluated by the same trained and uninformed rehabilitation physician. All patients provided their informed consent in writing. The study was approved by the Ethics Committee of Shanghai Eighth People's Hospital and is governed according to the principles of the Declaration of Helsinki.